Author:
Kerschbaum Julia,Rudnicki Michael,Dzien Alexander,Dzien-Bischinger Christine,Winner Hannes,Heerspink Hiddo Lambers,Rosivall László,Wiecek Andrzej,Mark Patrick B.,Eder Susanne,Denicolò Sara,Mayer Gert
Abstract
AbstractStudies reporting on biomarkers aiming to predict adverse renal outcomes in patients with type 2 diabetes and kidney disease (DKD) conventionally define a surrogate endpoint either as a percentage of decrease of eGFR (e.g. ≥ 30%) or an absolute decline (e.g. ≥ 5 ml/min/year). The application of those study results in clinical practise however relies on the assumption of a linear and intra-individually stable progression of DKD. We studied 860 patients of the PROVALID study and 178 of an independent population with a relatively preserved eGFR at baseline and at least 5 years of follow up. Individuals with a detrimental prognosis were identified using various thresholds of a percentage or absolute decline of eGFR after each year of follow up. Next, we determined how many of the patients met the same criteria at other points in time. Interindividual eGFR decline was highly variable but in addition intra-individual eGFR trajectories also were frequently non-linear. For example, of all subjects reaching an endpoint defined as a decrease of eGFR by ≥ 30% between baseline and 3 years of follow up, only 60.3 and 45.2% lost at least the same amount between baseline and year 4 or 5. The results were similar when only patients on stable medication or subpopulations based on baseline eGFR or albuminuria status were analyzed or an eGFR decline of ≥ 5 ml/min/1.73m2/year was used. Identification of reliable biomarkers predicting adverse prognosis is a strong clinical need given the large interindividual variability of DKD progression. However, it is conceptually challenging in early DKD because of non-linear intra-individual eGFR trajectories. As a result, the performance of a prognostic biomarker may be accurate after a specific time of follow-up in a single population only.
Funder
Innovative Medicines Initiative 2 Joint undertaking
AbbVie Deutschland
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2016. Amsterdam UMC, location AMC, Department of Medical Informatics, Amsterdam, the Netherlands, https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2016.pdf (2018).
2. Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Diabetic kidney disease: challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12, 2032–2045. https://doi.org/10.2215/CJN.11491116 (2017).
3. Finne, P. et al. Cumulative risk of end-stage renal disease among patients with type 2 diabetes: a nationwide inception cohort study. Diabetes Care 42, 539–544. https://doi.org/10.2337/dc18-1485 (2019).
4. Rawshani, A. et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N. Engl. J. Med. 376, 1407–1418. https://doi.org/10.1056/NEJMoa1608664 (2017).
5. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305. https://doi.org/10.1056/NEJMoa041031 (2004).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献